First 1,000 patients treated with impella 5.5 with smartassist, a heart pump designed for surgeons

Danvers, mass.--(business wire)--abiomed (nasdaq: abmd) announces 1,000 patients have been treated with the impella 5.5 with smartassist heart pump in the first year after the u.s. food and drug administration (fda) granted impella 5.5 with smartassist its highest level of approval for safety and efficacy. in october 2019, the first u.s. patients were successfully treated by cardiac surgeons at cleveland clinic, hackensack meridian health and cedars-sinai medical center. since then, more than 1
ABMD Ratings Summary
ABMD Quant Ranking